NEW YORK (GenomeWeb News) – Investment bank ISI Group this week downgraded shares of PerkinElmer and upgraded shares of Danaher.

In a research note, analyst Ross Muken lowered the rating for PerkinElmer to Neutral from Buy, saying that the company's stock is "now approaching the upper end of its historical range, and therefore we see limited opportunity for multiple expansion." He maintained a $49 price target on PerkinElmer's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.